Theoretical considerations for the ideal aromatase inhibitor

Area of Science:

• Endocrinology and Pharmacology
• Oncology and Cancer Therapeutics

Background:

• Aromatase inhibitors are crucial in managing hormone-dependent breast cancer.
• Complete inhibition of aromatase enzyme activity is a key theoretical component of ideal inhibitors.

Purpose of the Study:

• To define theoretical components of an ideal aromatase inhibitor, focusing on complete enzyme inhibition.
• To evaluate the efficacy of three triazole inhibitors (letrozole, vorozole, anastrozole) compared to aminoglutethimide.

Main Methods:

• Analysis of theoretical components for ideal aromatase inhibitors.
• Review of clinical trial data comparing letrozole, vorozole, and anastrozole with aminoglutethimide.
• Assessment of whole-body aromatisation inhibition percentages at clinical doses.

Main Results:

• Letrozole, vorozole, and anastrozole achieve >96% whole-body aromatisation inhibition at clinical doses.
• Vorozole and letrozole demonstrated greater efficacy in Phase III trials than aminoglutethimide (<90% inhibition).
• Minor differences between triazole inhibitors may correlate with clinical effectiveness.

Conclusions:

• The triazole aromatase inhibitors (letrozole, vorozole, anastrozole) represent significant advancements in enzyme inhibition.
• These compounds show potential for improved clinical outcomes in breast cancer treatment.
• Further consideration for breast cancer prevention studies is warranted for these advanced inhibitors.